Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.

To determine whether microcrystalline hydroxyapatite compound (MCHC) could reduce bone loss or its consequences in patients with chronic active hepatitis (CAH) on corticosteroid therapy, a controlled trial was conducted in 36 such patients over a period of 2 years. Both skeletal symptoms (back pain)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stellon, A., Davies, A., Webb, A., Williams, R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 1985
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2418401/
https://ncbi.nlm.nih.gov/pubmed/2997764
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak